DrugDashboards

Bupivacaine Hydrochloride

Bupivacaine Hydrochloride · BUPIVACAINE HYDROCHLORIDE 5 mg/mL · Injection, Solution · Epidural; Intracaudal; Perineural · Hospira, Inc.

NDC 00409-1162-02 · 25 VIAL, SINGLE-DOSE in 1 TRAY / 30 mL in 1 VIAL, SINGLE-DOSE · ANDA · View full market →

The short version

17 companies supply this market — deep enough that no single failure threatens the supply. It is in shortage right now — FDA lists the reason as “discontinuation of the manufacture of the drug”.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Medicare Part B pays (ASP+6%)$0.0110per billing unit (0.5 MG)HCPCS J0665 · Jul 1, 2026
  • Federal contracts pay (FSS)$36.03per package of 25X30MLPfizer Inc. · Jul 1, 2024

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed
$66.94
Reported to Texas DSHS · 2026 annual filing · Pfizer Inc.

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 0.5 MG
$0.011
HCPCS J0665 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$62,794
12,705 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.6%chance of a new FDA shortage posting for bupivacaine hydrochloride (injectable) in the next 90 days

sterile injectable · OAI inspection at a producing facility (24 months) · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is 4× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA070584
TE code
AP
Approval date
Feb 17, 1986
Patents / exclusivity
None on file

Shortage history

  • In shortage now — Bupivacaine Hydrochloride PRESERVATIVE FREE, Injection, 2.5 mg/1 mL (NDC 72266-263-10)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 14% odds it resolves within 6 months
  • In shortage now — Bupivacaine Hydrochloride, Injection, 0.25%; 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-10)Feb 20, 2018
    Discontinuation of the manufacture of the drug
    month 103 — 5× the typical 20-month injectable shortage · model puts 14% odds it resolves within 6 months
  • In shortage now — Bupivacaine Hydrochloride, Injection, 125 mg/50 mL (2.5 mg/mL) (NDC 0409-1160-01)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 14% odds it resolves within 6 months
  • In shortage now — Bupivacaine Hydrochloride, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-1162-02)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 14% odds it resolves within 6 months
  • In shortage now — Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 31722-275-32)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 14% odds it resolves within 6 months
  • In shortage now — Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 31722-275-34)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 14% odds it resolves within 6 months
  • In shortage now — Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-167-10)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 14% odds it resolves within 6 months
  • In shortage now — Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-168-30)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 14% odds it resolves within 6 months
  • In shortage now — Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-249-50)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 14% odds it resolves within 6 months
  • In shortage now — Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-01)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 14% odds it resolves within 6 months
  • In shortage now — Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-10)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 14% odds it resolves within 6 months
  • In shortage now — Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-25)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 14% odds it resolves within 6 months
  • In shortage now — Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-722-32)Feb 20, 2018
    Discontinuation of the manufacture of the drug
    month 103 — 5× the typical 20-month injectable shortage · model puts 14% odds it resolves within 6 months
  • In shortage now — Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-723-52)Feb 20, 2018
    Discontinuation of the manufacture of the drug
    month 103 — 5× the typical 20-month injectable shortage · model puts 14% odds it resolves within 6 months
  • In shortage now — Bupivacaine Hydrochloride, Injection, 225 mg/30 mL (7.5 mg/mL) (NDC 0409-1165-02)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 14% odds it resolves within 6 months
  • In shortage now — Bupivacaine Hydrochloride, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1159-01)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 14% odds it resolves within 6 months
  • In shortage now — Bupivacaine Hydrochloride, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-1163-01)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 14% odds it resolves within 6 months
  • In shortage now — Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 31722-276-32)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 14% odds it resolves within 6 months
  • In shortage now — Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 31722-276-34)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 14% odds it resolves within 6 months
  • In shortage now — Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-169-10)Feb 20, 2018
    month 103 — 5× the typical 20-month injectable shortage · model puts 14% odds it resolves within 6 months

Recalls (this NDC)

  • Class II · TerminatedApr 13, 2022
    Mckesson Medical-Surgical Inc. Corporate Office — cGMP deviations: Temperature abuse
  • Class I · TerminatedMay 3, 2021
    PFIZER, INC — Labeling: Label Mix-Up: some vials labeled to contain 0.5% Bupivacaine Hydrochloride Injection, USP may contain 1% Lidocaine HCl Injection, USP and some vials labeled to contain 1% Lidocaine HCl Injection, USP may contain 0.5% Bupivacaine Hydrochloride Injection, USP
  • Class I · OngoingAug 4, 2016
    Hospira Inc., A Pfizer Company — Presence of particulate matter: Confirmed customer report for the presence of particulate matter within a single vial.
  • Class I · TerminatedApr 23, 2015
    Hospira Inc. — Presence of Particulate Matter: Presence of free-floating and embedded iron oxide particles.
  • Class II · TerminatedSep 4, 2014
    Hospira Inc. — Presence of Particulate Matter: A confirmed customer complaint reported the presence of a brown, rust-colored particle embedded at the bottom of the glass vial.
  • Class II · TerminatedFeb 10, 2014
    Hospira Inc. — Presence of Particulate Matter: Confirmed customer report of visible particulate embedded in the glass vial.
  • Class II · TerminatedOct 11, 2013
    Hospira Inc. — Lack of assurance of sterility; equipment failure led to potential breach in asceptic process.
  • Class II · TerminatedSep 5, 2013
    Hospira Inc. — Lack of Assurance of Sterility; potential for vial breakage
  • Class I · TerminatedJul 12, 2013
    Hospira Inc. — Presence of particulate matter: visible free floating and partially embedded particulate matter in the glass vials.
  • Class I · TerminatedJul 12, 2013
    Hospira Inc. — Presence of particulate matter: visible free floating and partially embedded particulate matter in the glass vials.

Manufacturers of Bupivacaine Hydrochloride (Injection, Solution)

LabelerStrengthFirst seenLast seen
Asclemed USA, Inc.BUPIVACAINE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 3, 2026
Eugia US LLCBUPIVACAINE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 3, 2026
Eugia US LLCBUPIVACAINE HYDROCHLORIDE 2.5 mg/mLJul 15, 2026Sep 3, 2026
Fresenius Kabi USA, LLCBUPIVACAINE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 3, 2026
Fresenius Kabi USA, LLCBUPIVACAINE HYDROCHLORIDE 2.5 mg/mLJul 15, 2026Sep 3, 2026
Henry Schein, Inc.BUPIVACAINE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 3, 2026
Henry Schein, Inc.BUPIVACAINE HYDROCHLORIDE 2.5 mg/mLJul 15, 2026Sep 3, 2026
Hikma Pharmaceuticals USA Inc.BUPIVACAINE HYDROCHLORIDE 2.5 mg/mLJul 15, 2026Sep 3, 2026
Hikma Pharmaceuticals USA Inc.BUPIVACAINE HYDROCHLORIDE 7.5 mg/mLJul 15, 2026Sep 3, 2026
Hikma Pharmaceuticals USA Inc.BUPIVACAINE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 3, 2026
Hospira, Inc.BUPIVACAINE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 3, 2026
Hospira, Inc.BUPIVACAINE HYDROCHLORIDE 7.5 mg/mLJul 15, 2026Sep 3, 2026
Hospira, Inc.BUPIVACAINE HYDROCHLORIDE 2.5 mg/mLJul 15, 2026Sep 3, 2026
NorthStar RxLLCBUPIVACAINE HYDROCHLORIDE 7.5 mg/mLJul 15, 2026Sep 3, 2026
Onesource Specialty Pharma LimitedBUPIVACAINE HYDROCHLORIDE 2.5 mg/mLJul 15, 2026Sep 3, 2026
Onesource Specialty Pharma LimitedBUPIVACAINE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 3, 2026
Onesource Specialty Pharma LimitedBUPIVACAINE HYDROCHLORIDE 7.5 mg/mLJul 15, 2026Sep 3, 2026
Xellia Pharmaceuticals USA LLCBUPIVACAINE HYDROCHLORIDE 7.5 mg/mLJul 15, 2026Sep 3, 2026
Xellia Pharmaceuticals USA LLCBUPIVACAINE HYDROCHLORIDE 2.5 mg/mLJul 15, 2026Sep 3, 2026
A-S Medication SolutionsBUPIVACAINE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 2, 2026
Anthea Pharma Private LimitedBUPIVACAINE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 2, 2026
Anthea Pharma Private LimitedBUPIVACAINE HYDROCHLORIDE 2.5 mg/mLJul 15, 2026Sep 2, 2026
Anthea Pharma Private LimitedBUPIVACAINE HYDROCHLORIDE 7.5 mg/mLJul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.BUPIVACAINE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.BUPIVACAINE HYDROCHLORIDE 7.5 mg/mLJul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.BUPIVACAINE HYDROCHLORIDE 2.5 mg/mLJul 15, 2026Sep 2, 2026
Cardinal Health 107, LLCBUPIVACAINE HYDROCHLORIDE 2.5 mg/mLJul 15, 2026Sep 2, 2026
Fosun Pharma USA Inc.BUPIVACAINE HYDROCHLORIDE 2.5 mg/mLJul 15, 2026Sep 2, 2026
Fosun Pharma USA Inc.BUPIVACAINE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 2, 2026
Fresenius Kabi USA, LLCBUPIVACAINE HYDROCHLORIDE 7.5 mg/mLJul 15, 2026Sep 2, 2026
Henry Schein, IncBUPIVACAINE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 2, 2026
Henry Schein, IncBUPIVACAINE HYDROCHLORIDE 2.5 mg/mLJul 15, 2026Sep 2, 2026
HF Acquisition Co LLC, DBA HealthFirstBUPIVACAINE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 2, 2026
Hospira, Inc.BUPIVACAINE HYDROCHLORIDE 225 mg/30mLJul 15, 2026Sep 2, 2026
Hospira, Inc.BUPIVACAINE HYDROCHLORIDE 150 mg/30mLJul 15, 2026Sep 2, 2026
Hospira, Inc.BUPIVACAINE HYDROCHLORIDE 25 mg/10mLJul 15, 2026Sep 2, 2026
Hospira, Inc.BUPIVACAINE HYDROCHLORIDE 250 mg/50mLJul 15, 2026Sep 2, 2026
Hospira, Inc.BUPIVACAINE HYDROCHLORIDE 50 mg/10mLJul 15, 2026Sep 2, 2026
Hospira, Inc.BUPIVACAINE HYDROCHLORIDE 75 mg/30mLJul 15, 2026Sep 2, 2026
Medical Purchasing Solutions, LLCBUPIVACAINE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Bupivacaine Hydrochloride — NDC 00409-1162-02," retrieved September 3, 2026, https://drugdashboards.com/drug/00409116202.

Free to cite with attribution — see how the data is put together.